Paranoid/belligerence and neuroleptic dosage in newly admitted schizophrenic patients

Journal of Clinical Psychopharmacology

Volumn 17, Issue 2, 1997, Pages 84-87

  Troisi, Alfonso ^a   Pasini, Augusto ^a   De Angelis, Francesca ^a   Spalletta, Gianfranco ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOTIAPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; THIORIDAZINE;

ADOLESCENT; ADULT; AGED; ARTICLE; DEPRESSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARANOIA; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; CHLORPROMAZINE; FEMALE; HOSTILITY; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PARANOID BEHAVIOR; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0030973606     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199704000-00003     Document Type: Article

References (17)

1. Bollini P, Pampallona S, Orza MJ, Adams ME, Chalmers TC. Antipsychotic drugs: is more worse? A meta-analysis of the published randomized control trials. Psychol Med 1994;24: 307-16.
2. Volavka J, Cooper T, Czobor P, Meisner M. Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 1995;52:837-45.
3. Kane JM. The current status of neuroleptic therapy. J Clin Psychiatry 1989;50:322-8.
4. Davis JM, Barter JT, Kane JM. Antipsychotic drugs. In: Kaplan HI, Sadock BJ, eds. Comprehensive textbook of psychiatry. Baltimore: Williams & Wilkins, 1989:1591-626.
5. Reardon GT, Rifkin A, Schwartz A, Myerson A, Siris SG. Changing patterns of neuroleptic dosage over a decade. Am J Psychiatry 1989;146:726-9.
6. Remington G, Pollock B, Voineskos G, Reed K, Coulter K. Acutely psychotic patients receiving high-dose haloperidol therapy. J Clin Psychopharmacol 1993;13:41-5.
7. Krakowski MI, Kunz M, Czobor P, Volavka J. Long-term high-dose neuroleptic treatment: who gets it and why? Hosp Community Psychiatry 1993;44:640-4.
8. Peralta V, Cuesta MJ, Caro F, Martinez-Larrea A. Neuroleptic dose and schizophrenic symptoms. A survey of prescribing practices. Acta Psychiatr Scand 1994;90:354-7.
9. Kay SR. Positive and negative syndromes in schizophrenia: assessment and research. New York: Bruner/Mazel, 1991.
10. Spitzer RL, Williams JBW, Gibbon M. Structured Clinical Interview for DSM-III-R - Patient Version (SCID-P). New York: New York State Psychiatric Institute, Biometrics Research, 1987.
11. Rifkin A, Doddi S, Karajigi B, Borenstein M, Wachspress M. Dosage of haloperidol for schizophrenia. Arch Gen Psychiatry 1991;48:166-70.
12. Ratey JJ, Gordon A. The psychopharmacology of aggression: toward a new day. Psychopharmacol Bull 1993;29:65-73.
13. van Putten T, Mutaloipassi LR, Malkin MD. Phenotiazine-induced decompensation. Arch Gen Psychiatry 1974;30:102-5.
14. Yudofsky S, Silver J, Schneider S. Pharmacologic treatment of aggression. Psychiatr Ann 1987;17:397-407.
15. Ratey J, Sorgi P, Polakoff S. Nadolol as a treatment of akathisia. Am J Psychiatry 1985;142:640-2.
16. Goff DC, Midha KK, Brotman AW, McCormick S, Waiter M, Amica ET. An open trial of buspirone added to neuroleptics in schizophrenic patients. J Clin Psychopharmacol 1991;11:193-7.
17. Volavka J, Magno Zito J, Vitrai J, Czobor P. Clozapine effects on hostility and aggression in schizophrenia. J Clin Psychopharmacol 1993;13:287-9.